Skip to main content
Top
Published in: Infection 4/2023

Open Access 17-03-2023 | Obesity | Research

Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population

Authors: Laven Mavarani, Sarah Albayrak-Rena, Anja Potthoff, Martin Hower, Sebastian Dolff, Stefanie Sammet, Felix Maischack, Dirk Schadendorf, Börge Schmidt, Stefan Esser, on behalf of HIV HEART AGING Study

Published in: Infection | Issue 4/2023

Login to get access

Abstract

Purpose

Overweight and obesity have increased in people living with HIV (PLH). Our study evaluated weight, body-mass-index (BMI), and waist-to-hip ratio (WHR) change over 5 years of follow-up in PLH compared to the general population.

Methods

HIV-positive participants in the HIV Heart Aging (HIVH) study were matched 1:2 by age and sex with HIV-negative controls of the population-based Heinz Nixdorf Recall (HNR) study. Both studies were recruited in the German Ruhr area. The association between HIV and weight, BMI, and WHR changes was examined using linear regression. Regression models were adjusted for parameters potentially affecting weight gain.

Results

The matched HIVH and HNR participants (N = 585 and N = 1170, respectively; 14.7% females) had a mean age of 55 years at baseline. Despite the lower baseline weight (− 6 kg, 95% CI − 7.46 to − 4.59), the linear regression showed greater absolute and relative weight and BMI increases after 5 years in HIVH compared to HNR. Adjusting the linear regression models for smoking amplified that HIVH had a higher absolute and relative weight difference of 0.7 kg or ~ 1% compared to HNR after 5 years (95% Cl 0.1 to 1.3 and 0.2 to 1.6, respectively). Adjusting for HDL, LDL, systolic blood pressure, and diabetes mellitus did not affect the results.

Conclusions

PLH had lower weight than the general population at baseline and after 5 years, but experienced greater increases in body weight after 5 years. WHR change after 5 years was lower in PLH compared to the general population, despite a higher WHR at baseline.
Appendix
Available only for authorised users
Literature
2.
go back to reference Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9· 1 million participants. The Lancet. 2011;377:557–67.CrossRef Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9· 1 million participants. The Lancet. 2011;377:557–67.CrossRef
3.
go back to reference Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the united states and canada. AIDS Res Hum Retroviruses. 2016;32:50–8.CrossRefPubMedPubMedCentral Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the united states and canada. AIDS Res Hum Retroviruses. 2016;32:50–8.CrossRefPubMedPubMedCentral
4.
go back to reference Bailin SS, Gabriel CL, Fan R, Ye F, Nair S, Terry JG, et al. Relationship of subcutaneous adipose tissue inflammation-related gene expression with ectopic lipid deposition in persons with hiv. J Acquir Immune Defic Syndr. 2022;90:175–83.CrossRefPubMedPubMedCentral Bailin SS, Gabriel CL, Fan R, Ye F, Nair S, Terry JG, et al. Relationship of subcutaneous adipose tissue inflammation-related gene expression with ectopic lipid deposition in persons with hiv. J Acquir Immune Defic Syndr. 2022;90:175–83.CrossRefPubMedPubMedCentral
5.
go back to reference Garcia JM, Dong Y, Richardson P, Kramer JR, Hartman CM, Royse K, et al. Effect of hiv and antiretroviral therapy use on body weight changes in a cohort of U.S. Veterans living with and without hiv. HIV Med. 2023;24:180–90.CrossRefPubMed Garcia JM, Dong Y, Richardson P, Kramer JR, Hartman CM, Royse K, et al. Effect of hiv and antiretroviral therapy use on body weight changes in a cohort of U.S. Veterans living with and without hiv. HIV Med. 2023;24:180–90.CrossRefPubMed
7.
8.
go back to reference Bakal D, Coelho L, Luz PM, Clark JL, De Boni R, Cardoso SW, et al. Obesity following antiretroviral therapy (art) initiation is common and influenced by both traditional and hiv-/art-specific risk factors. Open Forum Infect Dis. 2017;4:S37–8.CrossRefPubMedCentral Bakal D, Coelho L, Luz PM, Clark JL, De Boni R, Cardoso SW, et al. Obesity following antiretroviral therapy (art) initiation is common and influenced by both traditional and hiv-/art-specific risk factors. Open Forum Infect Dis. 2017;4:S37–8.CrossRefPubMedCentral
9.
go back to reference Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: Weight gain in persons with hiv switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76:527–31.CrossRefPubMedPubMedCentral Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: Weight gain in persons with hiv switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017;76:527–31.CrossRefPubMedPubMedCentral
10.
go back to reference Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31:1499–500.CrossRefPubMed Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S, et al. Dolutegravir and weight gain: an unexpected bothering side effect? AIDS. 2017;31:1499–500.CrossRefPubMed
12.
go back to reference Shikuma C, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis. 2004;39:1223–30.CrossRefPubMed Shikuma C, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, et al. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis. 2004;39:1223–30.CrossRefPubMed
13.
go back to reference Piché M-E, Tchernof A, Després J-P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126:1477–500.CrossRefPubMed Piché M-E, Tchernof A, Després J-P. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126:1477–500.CrossRefPubMed
14.
go back to reference Physical status: the use and interpretation of anthropometry. Report of a who expert committee. World Health Organ Tech Rep Ser. 1995;854:1–452. Physical status: the use and interpretation of anthropometry. Report of a who expert committee. World Health Organ Tech Rep Ser. 1995;854:1–452.
15.
go back to reference McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, et al. Association between weight gain and the incidence of cardiometabolic conditions among people living with hiv-1 at high risk of weight gain initiated on antiretroviral therapy. Infect Dis Ther. 2022;11:1883–99.CrossRefPubMedPubMedCentral McComsey GA, Emond B, Shah A, Bookhart BK, Rossi C, Milbers K, et al. Association between weight gain and the incidence of cardiometabolic conditions among people living with hiv-1 at high risk of weight gain initiated on antiretroviral therapy. Infect Dis Ther. 2022;11:1883–99.CrossRefPubMedPubMedCentral
16.
go back to reference Bannister WP, Mast TC, de Wit S, Gerstoft J, Wiese L, Milinkovic A, et al. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens. AIDS. 2022;36:2107–19.CrossRefPubMed Bannister WP, Mast TC, de Wit S, Gerstoft J, Wiese L, Milinkovic A, et al. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens. AIDS. 2022;36:2107–19.CrossRefPubMed
17.
go back to reference Milic J, Renzetti S, Ferrari D, Barbieri S, Menozzi M, Carli F, et al. Relationship between weight gain and insulin resistance in people living with hiv switching to integrase strand transfer inhibitors-based regimens. AIDS. 2022;36:1643–53.CrossRefPubMed Milic J, Renzetti S, Ferrari D, Barbieri S, Menozzi M, Carli F, et al. Relationship between weight gain and insulin resistance in people living with hiv switching to integrase strand transfer inhibitors-based regimens. AIDS. 2022;36:1643–53.CrossRefPubMed
18.
go back to reference Gomez M, Seybold U, Roider J, Härter G, Bogner JR. A retrospective analysis of weight changes in hiv-positive patients switching from a tenofovir disoproxil fumarate (tdf)- to a tenofovir alafenamide fumarate (taf)-containing treatment regimen in one german university hospital in 2015–2017. Infection. 2019;47:95–102.CrossRefPubMed Gomez M, Seybold U, Roider J, Härter G, Bogner JR. A retrospective analysis of weight changes in hiv-positive patients switching from a tenofovir disoproxil fumarate (tdf)- to a tenofovir alafenamide fumarate (taf)-containing treatment regimen in one german university hospital in 2015–2017. Infection. 2019;47:95–102.CrossRefPubMed
19.
go back to reference Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat hiv. N Engl J Med. 2019;381:803–15.CrossRefPubMed Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat hiv. N Engl J Med. 2019;381:803–15.CrossRefPubMed
20.
go back to reference Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of hiv-1. N Engl J Med. 2019;381:816–26.CrossRefPubMed Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, et al. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of hiv-1. N Engl J Med. 2019;381:816–26.CrossRefPubMed
21.
go back to reference Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67:411–9.CrossRefPubMedPubMedCentral Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67:411–9.CrossRefPubMedPubMedCentral
22.
go back to reference Wellens RI, Roche AF, Khamis HJ, Jackson AS, Pollock ML, Siervogel RM. Relationships between the body mass index and body composition. Obes Res. 1996;4:35–44.CrossRefPubMed Wellens RI, Roche AF, Khamis HJ, Jackson AS, Pollock ML, Siervogel RM. Relationships between the body mass index and body composition. Obes Res. 1996;4:35–44.CrossRefPubMed
24.
go back to reference Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009;89:500–8.CrossRefPubMed Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009;89:500–8.CrossRefPubMed
25.
go back to reference de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007;28:850–6.CrossRefPubMed de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007;28:850–6.CrossRefPubMed
26.
27.
go back to reference Willett W. Nutritional epidemiology. Oxford University Press; 2012. Willett W. Nutritional epidemiology. Oxford University Press; 2012.
28.
go back to reference Seidell J, Han T, Feskens EJ, Lean M. Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med. 1997;242:401–6.CrossRefPubMed Seidell J, Han T, Feskens EJ, Lean M. Narrow hips and broad waist circumferences independently contribute to increased risk of non-insulin-dependent diabetes mellitus. J Intern Med. 1997;242:401–6.CrossRefPubMed
29.
go back to reference Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F, Neubans K, Kondratieva J, Buck T, Muller-Tasch T. Prevalence and natural history of heart failure in outpatient hiv-infected subjects: rationale and design of the hiv-heart study. Eur J Med Res. 2007;12:243.PubMed Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F, Neubans K, Kondratieva J, Buck T, Muller-Tasch T. Prevalence and natural history of heart failure in outpatient hiv-infected subjects: rationale and design of the hiv-heart study. Eur J Med Res. 2007;12:243.PubMed
30.
go back to reference Schmermund A, Möhlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jöckel KH. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the heinz nixdorf recall study. Am Heart J. 2002;144:212–8.CrossRefPubMed Schmermund A, Möhlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jöckel KH. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the heinz nixdorf recall study. Am Heart J. 2002;144:212–8.CrossRefPubMed
31.
go back to reference Kehrmann J, Menzel J, Saeedghalati M, Obeid R, Schulze C, Holzendorf V, et al. Gut microbiota in human immunodeficiency virus–infected individuals linked to coronary heart disease. J Infect Dis. 2018;219:497–508.CrossRef Kehrmann J, Menzel J, Saeedghalati M, Obeid R, Schulze C, Holzendorf V, et al. Gut microbiota in human immunodeficiency virus–infected individuals linked to coronary heart disease. J Infect Dis. 2018;219:497–508.CrossRef
33.
go back to reference Waist circumference and waist-hip ratio. In: Organization WH, editor; 2008. p. 39. Waist circumference and waist-hip ratio. In: Organization WH, editor; 2008. p. 39.
34.
go back to reference Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther. 2011;90:164–8.CrossRefPubMed Audrain-McGovern J, Benowitz NL. Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther. 2011;90:164–8.CrossRefPubMed
35.
go back to reference Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naïve persons with hiv starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the united states and canada. J Int AIDS Soc. 2020;23: e25484.CrossRefPubMedPubMedCentral Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naïve persons with hiv starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the united states and canada. J Int AIDS Soc. 2020;23: e25484.CrossRefPubMedPubMedCentral
36.
go back to reference Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73:1440–51.CrossRefPubMed Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021;73:1440–51.CrossRefPubMed
37.
go back to reference Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379–89.CrossRefPubMed Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379–89.CrossRefPubMed
38.
go back to reference Visnegarwala F, Raghavan SS, Mullin CM, Bartsch G, Wang J, Kotler D, et al. Sex differences in the associations of hiv disease characteristics and body composition in antiretroviral-naive persons. Am J Clin Nutr. 2005;82:850–6.CrossRefPubMed Visnegarwala F, Raghavan SS, Mullin CM, Bartsch G, Wang J, Kotler D, et al. Sex differences in the associations of hiv disease characteristics and body composition in antiretroviral-naive persons. Am J Clin Nutr. 2005;82:850–6.CrossRefPubMed
39.
go back to reference Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, et al. Impact of hiv infection on total body composition in treatment-naive men evaluated by dual-energy x-ray absorptiometry comparison of 90 untreated hiv-infected men to 241 controls. J Clin Densitom. 2007;10:376–80.CrossRefPubMed Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, et al. Impact of hiv infection on total body composition in treatment-naive men evaluated by dual-energy x-ray absorptiometry comparison of 90 untreated hiv-infected men to 241 controls. J Clin Densitom. 2007;10:376–80.CrossRefPubMed
40.
go back to reference Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. Hiv and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6:48.CrossRefPubMed Koethe JR, Lagathu C, Lake JE, Domingo P, Calmy A, Falutz J, et al. Hiv and antiretroviral therapy-related fat alterations. Nat Rev Dis Primers. 2020;6:48.CrossRefPubMed
41.
go back to reference Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60:1852–9.CrossRefPubMedPubMedCentral Yuh B, Tate J, Butt AA, Crothers K, Freiberg M, Leaf D, et al. Weight change after antiretroviral therapy and mortality. Clin Infect Dis. 2015;60:1852–9.CrossRefPubMedPubMedCentral
42.
go back to reference Dimala CA, Ngu RC, Kadia BM, Tianyi FL, Choukem SP. Markers of adiposity in hiv/aids patients: agreement between waist circumference, waist-to-hip ratio, waist-to-height ratio and body mass index. PLoS ONE. 2018;13: e0194653.CrossRefPubMedPubMedCentral Dimala CA, Ngu RC, Kadia BM, Tianyi FL, Choukem SP. Markers of adiposity in hiv/aids patients: agreement between waist circumference, waist-to-hip ratio, waist-to-height ratio and body mass index. PLoS ONE. 2018;13: e0194653.CrossRefPubMedPubMedCentral
43.
go back to reference Taramasso L, Bonfanti P, Ricci E, Maggi P, Orofino G, Squillace N, et al. Metabolic syndrome and body weight in people living with hiv infection: Analysis of differences observed in three different cohort studies over a decade. HIV Med. 2022;23:70–9.CrossRefPubMed Taramasso L, Bonfanti P, Ricci E, Maggi P, Orofino G, Squillace N, et al. Metabolic syndrome and body weight in people living with hiv infection: Analysis of differences observed in three different cohort studies over a decade. HIV Med. 2022;23:70–9.CrossRefPubMed
44.
go back to reference Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with hiv antiretroviral treatment. Expert Opin Drug Saf. 2019;18:829–40.CrossRefPubMed Lagathu C, Béréziat V, Gorwood J, Fellahi S, Bastard JP, Vigouroux C, et al. Metabolic complications affecting adipose tissue, lipid and glucose metabolism associated with hiv antiretroviral treatment. Expert Opin Drug Saf. 2019;18:829–40.CrossRefPubMed
45.
go back to reference Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: From wasting to obesity: initial antiretroviral therapy and weight gain in hiv-infected persons. AIDS Res Hum Retroviruses. 2013;29:435–40.CrossRefPubMedPubMedCentral Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: From wasting to obesity: initial antiretroviral therapy and weight gain in hiv-infected persons. AIDS Res Hum Retroviruses. 2013;29:435–40.CrossRefPubMedPubMedCentral
Metadata
Title
Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population
Authors
Laven Mavarani
Sarah Albayrak-Rena
Anja Potthoff
Martin Hower
Sebastian Dolff
Stefanie Sammet
Felix Maischack
Dirk Schadendorf
Börge Schmidt
Stefan Esser
on behalf of HIV HEART AGING Study
Publication date
17-03-2023
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 4/2023
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-023-02009-8

Other articles of this Issue 4/2023

Infection 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.